Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 25 | 2023 | 89 | 6.270 |
Why?
|
| Prostate | 13 | 2022 | 30 | 3.500 |
Why?
|
| Kidney Neoplasms | 13 | 2023 | 66 | 2.840 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2023 | 40 | 2.000 |
Why?
|
| Image-Guided Biopsy | 11 | 2022 | 32 | 1.710 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2022 | 1140 | 1.420 |
Why?
|
| Robotic Surgical Procedures | 4 | 2023 | 26 | 1.190 |
Why?
|
| Robotics | 3 | 2023 | 16 | 1.090 |
Why?
|
| Nephrectomy | 8 | 2017 | 30 | 0.930 |
Why?
|
| Nomograms | 1 | 2021 | 5 | 0.780 |
Why?
|
| Germ-Line Mutation | 3 | 2016 | 11 | 0.760 |
Why?
|
| Male | 43 | 2023 | 14025 | 0.750 |
Why?
|
| Humans | 52 | 2023 | 26049 | 0.660 |
Why?
|
| Waiting Lists | 1 | 2017 | 15 | 0.590 |
Why?
|
| Kidney Transplantation | 3 | 2017 | 120 | 0.570 |
Why?
|
| Renal Dialysis | 1 | 2017 | 107 | 0.540 |
Why?
|
| Retrospective Studies | 13 | 2023 | 3305 | 0.540 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 3 | 0.530 |
Why?
|
| Ultrasonography, Interventional | 6 | 2020 | 64 | 0.520 |
Why?
|
| Heterozygote | 1 | 2016 | 92 | 0.510 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 13 | 0.510 |
Why?
|
| Laparoscopy | 4 | 2023 | 159 | 0.470 |
Why?
|
| Ultrasonography | 6 | 2019 | 222 | 0.470 |
Why?
|
| Middle Aged | 28 | 2022 | 8511 | 0.460 |
Why?
|
| Biopsy | 6 | 2022 | 199 | 0.460 |
Why?
|
| Aged | 21 | 2022 | 8719 | 0.450 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 5 | 2020 | 9 | 0.400 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2017 | 28 | 0.390 |
Why?
|
| Perineum | 2 | 2021 | 7 | 0.390 |
Why?
|
| Kidney Diseases | 2 | 2012 | 100 | 0.350 |
Why?
|
| Biopsy, Large-Core Needle | 3 | 2021 | 8 | 0.340 |
Why?
|
| Prostatic Hyperplasia | 3 | 2013 | 8 | 0.330 |
Why?
|
| Ureter | 2 | 2023 | 18 | 0.300 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 23 | 0.270 |
Why?
|
| Prospective Studies | 6 | 2023 | 1663 | 0.270 |
Why?
|
| Kidney | 3 | 2023 | 155 | 0.270 |
Why?
|
| Urinary Tract Infections | 1 | 2006 | 29 | 0.270 |
Why?
|
| Adult | 14 | 2017 | 7367 | 0.240 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 4674 | 0.220 |
Why?
|
| Ureteral Obstruction | 1 | 2023 | 16 | 0.220 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 277 | 0.220 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2022 | 1 | 0.210 |
Why?
|
| Cystectomy | 2 | 2019 | 6 | 0.200 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 31 | 0.190 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 4 | 0.190 |
Why?
|
| Prostatectomy | 2 | 2023 | 19 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2004 | 11 | 0.170 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 457 | 0.170 |
Why?
|
| Urinary Bladder | 1 | 2019 | 19 | 0.170 |
Why?
|
| Urology | 1 | 2019 | 17 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 40 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 340 | 0.160 |
Why?
|
| Survival Rate | 2 | 2017 | 321 | 0.160 |
Why?
|
| United States | 4 | 2017 | 1981 | 0.150 |
Why?
|
| Female | 14 | 2017 | 14411 | 0.150 |
Why?
|
| Ablation Techniques | 1 | 2017 | 2 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2017 | 22 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 49 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 32 | 0.140 |
Why?
|
| Phototherapy | 1 | 2017 | 24 | 0.140 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 3 | 0.140 |
Why?
|
| ErbB Receptors | 1 | 2017 | 51 | 0.140 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 17 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2017 | 48 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 38 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 171 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 5 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 3 | 2004 | 8 | 0.130 |
Why?
|
| Succinate Dehydrogenase | 1 | 2015 | 1 | 0.120 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2015 | 2 | 0.120 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 3 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 151 | 0.120 |
Why?
|
| Animals | 5 | 2017 | 3391 | 0.120 |
Why?
|
| Disease Management | 2 | 2016 | 108 | 0.120 |
Why?
|
| Neoplasm Grading | 4 | 2018 | 45 | 0.120 |
Why?
|
| Kallikreins | 1 | 2014 | 1 | 0.120 |
Why?
|
| Prognosis | 5 | 2017 | 750 | 0.120 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2013 | 3 | 0.110 |
Why?
|
| SEER Program | 4 | 2015 | 38 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2013 | 52 | 0.110 |
Why?
|
| Time Factors | 1 | 2017 | 1364 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 3 | 0.110 |
Why?
|
| Urothelium | 1 | 2013 | 4 | 0.110 |
Why?
|
| Estrogens | 1 | 2013 | 25 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2002 | 14 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 72 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 295 | 0.100 |
Why?
|
| Threonine | 1 | 2011 | 5 | 0.090 |
Why?
|
| Fungal Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 5 | 0.090 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 13 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 1713 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3293 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2016 | 235 | 0.080 |
Why?
|
| Watchful Waiting | 2 | 2022 | 9 | 0.080 |
Why?
|
| Nitriles | 2 | 2022 | 12 | 0.080 |
Why?
|
| Young Adult | 4 | 2015 | 1853 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 230 | 0.070 |
Why?
|
| Adolescent | 4 | 2015 | 2064 | 0.070 |
Why?
|
| Malacoplakia | 1 | 2006 | 1 | 0.070 |
Why?
|
| Pyelonephritis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Tuberculosis, Renal | 1 | 2006 | 1 | 0.070 |
Why?
|
| Emphysema | 1 | 2006 | 4 | 0.070 |
Why?
|
| Risk Factors | 3 | 2022 | 2246 | 0.070 |
Why?
|
| Abscess | 1 | 2006 | 26 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 342 | 0.060 |
Why?
|
| Child | 3 | 2015 | 1229 | 0.060 |
Why?
|
| Depsipeptides | 1 | 2004 | 1 | 0.060 |
Why?
|
| Burkitt Lymphoma | 1 | 2004 | 7 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2004 | 8 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 10 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 11 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 114 | 0.060 |
Why?
|
| Urologic Surgical Procedures | 1 | 2023 | 10 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2023 | 14 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2014 | 1829 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 9 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 714 | 0.050 |
Why?
|
| Organ Size | 2 | 2013 | 95 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 176 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2017 | 622 | 0.050 |
Why?
|
| Phenylthiohydantoin | 1 | 2022 | 2 | 0.050 |
Why?
|
| Benzamides | 1 | 2022 | 15 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 73 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 49 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 96 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 21 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2001 | 10 | 0.050 |
Why?
|
| Patient Selection | 2 | 2013 | 193 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2001 | 23 | 0.050 |
Why?
|
| HIV Infections | 1 | 2006 | 463 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 3 | 0.050 |
Why?
|
| Androgens | 1 | 2021 | 7 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 103 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 6 | 0.050 |
Why?
|
| Mice | 3 | 2017 | 1281 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 313 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 485 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 670 | 0.040 |
Why?
|
| Education | 1 | 2019 | 45 | 0.040 |
Why?
|
| Simulation Training | 1 | 2019 | 38 | 0.040 |
Why?
|
| Infrared Rays | 1 | 2017 | 1 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2017 | 4 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2017 | 7 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2002 | 862 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 192 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 2015 | 2 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 25 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 81 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 76 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 2 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 279 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2014 | 46 | 0.030 |
Why?
|
| Contrast Media | 1 | 2014 | 60 | 0.030 |
Why?
|
| Heredity | 1 | 2013 | 6 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 325 | 0.030 |
Why?
|
| Dutasteride | 1 | 2013 | 2 | 0.030 |
Why?
|
| Azasteroids | 1 | 2013 | 2 | 0.030 |
Why?
|
| Finasteride | 1 | 2013 | 2 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 55 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2013 | 26 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 25 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 24 | 0.030 |
Why?
|
| Age of Onset | 1 | 2013 | 92 | 0.030 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 3 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 2 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 13 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 33 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2004 | 16 | 0.030 |
Why?
|
| Propionates | 1 | 2013 | 13 | 0.030 |
Why?
|
| Michigan | 1 | 2013 | 16 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 14 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2013 | 24 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 69 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 216 | 0.030 |
Why?
|
| Nephrons | 1 | 2012 | 5 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 80 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 158 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 291 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2013 | 161 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 85 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 26 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 184 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 373 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 77 | 0.020 |
Why?
|
| Solvents | 1 | 2011 | 4 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 685 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 466 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 44 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 305 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 91 | 0.020 |
Why?
|
| Chaperonins | 1 | 2011 | 1 | 0.020 |
Why?
|
| Casein Kinase II | 1 | 2011 | 2 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 17 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 13 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 18 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 51 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 389 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 133 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 568 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 845 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 744 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 333 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 853 | 0.020 |
Why?
|
| Thymidine | 1 | 2004 | 7 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 4 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2004 | 3 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 20 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 79 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 43 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 109 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 108 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 193 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 1 | 0.010 |
Why?
|
| Zidovudine | 1 | 2003 | 13 | 0.010 |
Why?
|
| Ganciclovir | 1 | 2003 | 8 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 70 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 151 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 264 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 2001 | 3 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2001 | 38 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 29 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 39 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 598 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 281 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2001 | 48 | 0.010 |
Why?
|